Scandinavian Journal of Gastroenterology最新文献_第3页

Fecal calprotectin concentration in adults with and without Helicobacter pylori infection. 幽门螺杆菌感染和未感染的成人粪便钙保护蛋白浓度。

IF 1.8 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2026-10-01 Epub Date: 2026-07-01 DOI: 10.1080/00365521.2026.2694750

Tarek Mazzawi, Sameer A Al Haj Mahmoud

{"title":"Fecal calprotectin concentration in adults with and without Helicobacter pylori infection.","authors":"Tarek Mazzawi, Sameer A Al Haj Mahmoud","doi":"10.1080/00365521.2026.2694750","DOIUrl":"10.1080/00365521.2026.2694750","url":null,"abstract":"Background: Helicobacter pylori (H.p.) is a very common cause of chronic gastritis. As an acute phase protein, calprotectin (CP) has a significant function during inflammation. The aims were to investigate the difference of fecal CP concentration in adults with and without H.p. infection, the effect of eradication therapy on fecal CP concentration, and to correlate between fecal CP concentration and the grade of activity of chronic gastritis in both groups.Methods: Patients complaining of abdominal pain, referred to the gastroenterology outpatient clinic, were recruited in this prospective study. They provided stool samples to be tested for fecal CP, H.p. antigen and stool analysis with culture. Upper and lower endoscopies were offered, within 48 h, to all eligible patients with elevated fecal CP concentration irrespective of H.p. infectivity. Patients with H.p. infection received eradication treatment and were asked to provide a new stool sample to test fecal CP and H. pylori antigen.Results: A total of 186 patients (93 males and 93 females) were enrolled and divided into two groups according to their H.p. infectivity: 105 negative- and 81 positive-H.p. infection. Fecal CP concentration was significantly higher in the H.p. positive than negative group (p = 0·004) and significantly decreased (p < 0·0001) after receiving eradication therapy. Fecal CP concentration correlated significantly (r 0·60, p < 0·0001) with the grade of activity of H.p. induced gastritis.Conclusion: Fecal CP concentration can be affected by H.p. infection. Helicobacter pylori eradication may improve fecal CP concentration.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1076-1081"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148369625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stepwise accumulation of chromosomal copy number variations along the gastritis-carcinoma sequence: implications for early risk stratification in gastric cancer. 沿胃炎-癌序列的染色体拷贝数变异的逐步积累：胃癌早期风险分层的意义。

IF 1.8 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2026-10-01 Epub Date: 2026-07-09 DOI: 10.1080/00365521.2026.2698841

Xingyi Zhang, Tongyue Zhang, Ruiwei Shen, Xiaona Shao, Yunke Tian, Xiao Wu, Zhuolin Le, Jianwei Shen

{"title":"Stepwise accumulation of chromosomal copy number variations along the gastritis-carcinoma sequence: implications for early risk stratification in gastric cancer.","authors":"Xingyi Zhang, Tongyue Zhang, Ruiwei Shen, Xiaona Shao, Yunke Tian, Xiao Wu, Zhuolin Le, Jianwei Shen","doi":"10.1080/00365521.2026.2698841","DOIUrl":"10.1080/00365521.2026.2698841","url":null,"abstract":"Background: Gastric cancer poses a serious threat to public health, and the current screening is of limited efficiency. Chromosomal copy number variation (CNV) is a major driver of gastric carcinogenesis, yet its stepwise evolution along the gastritis-carcinoma sequence remains poorly delineated. Dissecting the dynamic landscape of CNVs may yield crucial biomarkers for early risk stratification.Methods: In this study, we performed cost-effective low-coverage whole-genome sequencing (LC-WGS) on 101 gastric mucosal specimens encompassing non-atrophic gastritis (NAG, n = 15), atrophic gastritis (AG, n = 35), high-grade intraepithelial neoplasia or early gastric cancer (HGIN/EGC, n = 33), and advanced gastric cancer (AGC, n = 18).Results: The frequency of CNV at both the complete chromosome and chromosomal-arm level showed a stepwise increase along the gastritis-carcinoma sequence. Two novel quantitative indices, MaxZ and CountZ, were developed to respectively measure the magnitude and extent of chromosomal imbalance, both of which correlated strongly with histologic progression (ρ > 0.4, p < 0.001). Recurrent alterations included gains on chromosomes 20, 8q and 7p and losses on chromosomes 4, which accumulated along the sequence and may represent key CNV events underlying malignant transformation. Notably, clustering analysis identified a high-CNV subgroup within AG (n = 5) exhibiting CNV profiles resembling gastric cancer.Conclusions: These preliminary CNV signatures suggest potential value for identifying high-risk individuals in precancerous lesions, particularly within AG, and offer an exploratory molecular basis that may inform future early screening and diagnosis of gastric cancer.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1065-1075"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148412823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological treatments for moderate-to-severe ulcerative colitis: a systematic review and Bayesian network meta-analysis. 中重度溃疡性结肠炎的药物治疗：系统综述和贝叶斯网络荟萃分析。

IF 1.8 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2026-10-01 Epub Date: 2026-07-25 DOI: 10.1080/00365521.2026.2698847

Jinzhi Qi, Qiangqiang Tian, Guangyuan Yang, Zhaofeng Chen

{"title":"Pharmacological treatments for moderate-to-severe ulcerative colitis: a systematic review and Bayesian network meta-analysis.","authors":"Jinzhi Qi, Qiangqiang Tian, Guangyuan Yang, Zhaofeng Chen","doi":"10.1080/00365521.2026.2698847","DOIUrl":"10.1080/00365521.2026.2698847","url":null,"abstract":"Backgrounds: To systematically compare the relative efficacy of different therapeutic agents for the induction and maintenance treatment of moderate-to-severe active ulcerative colitis (UC) in adult patients.Methods: We retrieved RCTs from PubMed, Embase, Scopus and CENTRAL (2020.1.1 - 2026.1.1). A Bayesian random-effects NMA was performed, with treatment efficacy ranked by SUCRA. (Registration No. CRD420261293873).Results: A total of 41 RCTs comprising 22,619 patients with moderate-to-severe active UC were included. Compared with placebo, JAK-STAT inhibitors (RR = 4.5, 95% CI 3.0-7.2), anti-TNF-α biologics (RR = 3.0, 95% CI 1.8-5.3), S1P receptor modulators (RR = 3.0, 95% CI 2.1-4.5), anti-IL-23 biologics (RR = 2.8, 95% CI 2.0-4.0), anti-integrin biologics (RR = 2.2, 95% CI 1.5-3.2) and anti-TL1A biologics (RR = 4.0, 95% CI 2.0-9.0) significantly improved clinical remission during the induction phase. Furthermore, JAK-STAT inhibitors, S1P receptor modulators, anti-IL-23 biologics, anti-TNF-α biologics, and anti-integrin biologics effectively maintained clinical remission. Monotherapy with 5-aminosalicylates (5-ASA) or immunomodulators did not demonstrate a significant benefit over placebo. Based on SUCRA probabilities, the top three regimens for induction of clinical remission were JAK-STAT inhibitors (91.5%), anti-TL1A biologics (82.3%), and anti-TNF-α biologics (70.1%). For the maintenance phase, the top three were JAK-STAT inhibitors (86.3%), S1P receptor modulators (80.5%), and anti-IL-23 biologics (59.4%).Conclusions: JAK-STAT inhibitors demonstrated optimal efficacy for achieving clinical remission in both the induction and maintenance phases of UC treatment. Additionally, targeted therapies, including anti-TNF-α, anti-IL-23, and S1P receptor modulators, provided substantial therapeutic benefits.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1089-1103"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148593375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and performance of small bowel capsule endoscopy in patients with surgically altered gastrointestinal anatomy. 小肠胶囊内镜在手术改变胃肠道解剖结构患者中的安全性和性能。

IF 1.8 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2026-10-01 Epub Date: 2026-07-02 DOI: 10.1080/00365521.2026.2696878

Zehra Naseem, Ridhima Kaul, Renan Prado, Arjun Chatterjee, Manik Aggarwal, Jason Nasser, Yueqi Wu, Qijun Yang, John McMichael, Rupayan Kundu, Cynthia Funk, Andrew Ford, C Roberto Simons-Linares, Alberto Rubio-Tapia

{"title":"Safety and performance of small bowel capsule endoscopy in patients with surgically altered gastrointestinal anatomy.","authors":"Zehra Naseem, Ridhima Kaul, Renan Prado, Arjun Chatterjee, Manik Aggarwal, Jason Nasser, Yueqi Wu, Qijun Yang, John McMichael, Rupayan Kundu, Cynthia Funk, Andrew Ford, C Roberto Simons-Linares, Alberto Rubio-Tapia","doi":"10.1080/00365521.2026.2696878","DOIUrl":"10.1080/00365521.2026.2696878","url":null,"abstract":"Background: To study the performance and efficacy of small bowel capsule endoscopy (SBCE) in a large cohort of patients with surgically altered gastrointestinal anatomy (SAGA).Methods: We retrospectively reviewed all SBCE studies between January 2000 and August 2025. Patients with SAGA (prior gastrectomy, gastric bypass, small bowel resections, esophagectomy, or Whipple procedures) were matched 1:2 to patients with native gastrointestinal (GI) anatomy. Primary outcome was SBCE completion rate. Secondary outcomes included diagnostic yield, capsule retention, and GI transit times.Results: A total of 102 patients with SAGA were matched to 204 patients with native GI anatomy. Gastric bypass was the most common surgical history among SAGA patients (n = 47; 46%). Use of patency capsule prior to SBCE ingestion was more frequent in the SAGA group (27% vs. 6%, p < 0.01). The most common indication for SBCE was overt GI bleeding (SAGA 43% vs. native 60%, p = 0.01).Completion rates were similar (SAGA 95% vs. native 94%, p = 0.93). Capsule retention requiring endoscopic or surgical retrieval occurred only in the native anatomy group (n = 3). Median total transit time was shorter in the SAGA group (731 vs. 818 min, p < 0.01), while median small bowel transit time was similar between the groups. Overall diagnostic yield was similar between the groups (SAGA: 48% vs. native GI anatomy: 57.4%, p = 0.13).Conclusions: SBCE is effective in patients with SAGA, demonstrating comparable completion rates and similar diagnostic yield to patients with native GI anatomy.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1037-1044"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148376615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes associated with secondary spontaneous bacterial peritonitis (SBP) prophylaxis after hospital discharge in a nation-wide Swedish cohort. 在瑞典全国队列中，与出院后继发性自发性细菌性腹膜炎（SBP）预防相关的结果。

IF 1.8 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2026-10-01 Epub Date: 2026-06-30 DOI: 10.1080/00365521.2026.2694752

Max Schechter, Linnea Widman, Ying Shang, Andrea Lindfors, Hannes Hagström, Axel Wester

{"title":"Outcomes associated with secondary spontaneous bacterial peritonitis (SBP) prophylaxis after hospital discharge in a nation-wide Swedish cohort.","authors":"Max Schechter, Linnea Widman, Ying Shang, Andrea Lindfors, Hannes Hagström, Axel Wester","doi":"10.1080/00365521.2026.2694752","DOIUrl":"10.1080/00365521.2026.2694752","url":null,"abstract":"Background and aims: Secondary spontaneous bacterial peritonitis (SBP) prophylaxis has been shown to reduce mortality. Recent evidence, however, suggests that SBP prophylaxis may lead to adverse outcomes such as antibiotic-resistant infections and increased SBP recurrence. Among patients with SBP, we evaluated the proportion who received SBP prophylaxis and its impact on readmission with SBP, readmission with other infections and mortality.Methods: We conducted a register-based cohort study identifying hospitalized patients in Sweden diagnosed with a first episode of SBP from the Swedish National Patient Register. The primary outcome was rates of rehospitalization due to SBP, and the secondary outcomes were rehospitalization with sepsis, Clostridium difficile and mortality. Logistic regression was used to assess factors associated with receiving SBP prophylaxis and Cox regression was used to assess the association between secondary prophylaxis and subsequent rehospitalizations and mortality.Results: Of 896 patients that met study criteria, 117 (13%) dispensed secondary SBP prophylaxis within 7 days of discharge. Using multivariable Cox regression, we found that receiving SBP prophylaxis was associated with the lower rates of readmission with SBP compared to patients that did not receive prophylaxis (aHR = 0.50, 95%CI = 0.28-0.89), with no significant increase in readmission with sepsis (aHR = 1.00, 95%CI = 0.20-4.93) or Clostridium difficile (aHR = 2.11, 95%CI = 0.71-6.25). No association with mortality was found (aHR = 0.96, 95%CI = 0.73-1.25).Conclusions: In this cohort, only 13% of patients dispensed secondary antibiotic prophylaxis. These patients may experience lower rates of rehospitalization with SBP; however, no effect on mortality was seen. Further investigation into the impact of secondary SBP prophylaxis is needed.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1138-1144"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148362216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing trial eligibility and real-world response to vedolizumab and ustekinumab in patients with ulcerative colitis. 评估溃疡性结肠炎患者对vedolizumab和ustekinumab的试验资格和实际反应。

IF 1.8 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2026-10-01 Epub Date: 2026-07-06 DOI: 10.1080/00365521.2026.2697982

Stephen Le Breton, Aditya Mithal, Tasnim Ahmed, Jini Huh, Konstantinos Papamichael, Adam S Cheifetz

{"title":"Assessing trial eligibility and real-world response to vedolizumab and ustekinumab in patients with ulcerative colitis.","authors":"Stephen Le Breton, Aditya Mithal, Tasnim Ahmed, Jini Huh, Konstantinos Papamichael, Adam S Cheifetz","doi":"10.1080/00365521.2026.2697982","DOIUrl":"10.1080/00365521.2026.2697982","url":null,"abstract":"Background: Biologic therapies for patients with inflammatory bowel disease (IBD) were approved via large randomized controlled trials (RCTs) with strict criteria for patient enrollment. As newer IBD medications are approved, ongoing assessment is necessary to determine whether RCT eligibility criteria are too restrictive or adequately reflect real-world practice. Here, we investigate the trial-eligibility and clinical outcomes of patients with ulcerative colitis (UC) started on vedolizumab (VDZ) and ustekinumab (UST) therapy.Methods: This single-center retrospective cohort study at a large academic IBD referral center included patients with UC who received a new prescription for UST or VDZ between January 2020 and June 2023. The primary outcome assessed whether patients met trial eligibility using the inclusion and exclusion criteria from the UNIFI and GEMINI-1 RCTs. We also assessed treatment failure between the trial-eligible and ineligible groups.Results: Only 19/168 (11.3%) of patients with UC (n = 85 receiving VDZ; n = 83 receiving UST) were trial-eligible. The most common reasons for ineligibility were prior biologics and inadequate wash-out periods, the use of topical therapy, medical comorbidities and ongoing treatment with high doses of prednisone. Treatment failure was numerically higher in trial-ineligible compared to trial-eligible patients, though this difference was not statistically significant.Conclusion: Most patients initiated on UST or VDZ would not have qualified for inclusion in their respective RCTs, largely due to current treatments. Revising trial eligibility criteria may be warranted to improve external validity and enable recruitment of a more diverse study population representative of real-world patients.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1082-1088"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148391715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diverging incidences of low-grade dysplasia and advanced neoplasia in inflammatory bowel disease: a nationwide Danish cohort study. 炎症性肠病中低度发育不良和晚期肿瘤的不同发病率：一项丹麦全国队列研究

IF 1.8 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2026-10-01 Epub Date: 2026-07-09 DOI: 10.1080/00365521.2026.2698840

Jesper Winkler Andersen, Frederikke Schønfeldt Troelsen, Klaus Krogh, Ailsa Hart, Anders Dige

{"title":"Diverging incidences of low-grade dysplasia and advanced neoplasia in inflammatory bowel disease: a nationwide Danish cohort study.","authors":"Jesper Winkler Andersen, Frederikke Schønfeldt Troelsen, Klaus Krogh, Ailsa Hart, Anders Dige","doi":"10.1080/00365521.2026.2698840","DOIUrl":"10.1080/00365521.2026.2698840","url":null,"abstract":"Background: In individuals with inflammatory bowel disease (IBD), low-grade dysplasia (LGD) is a risk factor for advanced neoplasia, that is, high-grade dysplasia and colorectal cancer. Over recent decades, advances in IBD management and endoscopic surveillance have been implemented; however, it remains unclear whether these developments have influenced the incidence of LGD and advanced neoplasia.Objective: To describe contemporary trends in the population-level incidence of LGD and advanced neoplasia in IBD.Design: We conducted a nationwide Danish cohort study (1990-2022) using national healthcare registers. IBD was defined at the second recorded healthcare contact with an IBD diagnosis. Annual age-standardised incidence rates (IRs) per 1,000 IBD patient-years were calculated for LGD and advanced neoplasia. Incidence rate ratios (IRRs) relative to 1990 were estimated using Poisson regression.Results: Among 78,126 individuals with IBD, we identified 6,814 incident cases of LGD and 1,987 of advanced neoplasia. The IR of LGD increased from 0.68 per 1,000 IBD patient-years in 1990 to 4.41 in 2022 (IRR 6.47, 95% confidence interval (CI) 3.99-10.49), with a sustained increase after the introduction of the national general colorectal cancer screening programme in 2014. In contrast, the IR of advanced neoplasia remained stable (IRR 1.10, 95% CI 0.59-2.07).Conclusion: The incidence of IBD-related LGD increased markedly over the study period, particularly after the introduction of the national general colorectal cancer screening programme in 2014, whereas the incidence of advanced neoplasia remained stable. These findings highlight the need for robust risk stratification to identify individuals who may benefit from surveillance.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1055-1064"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148412829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring obstacles to physical activity in inflammatory bowel disease: insights from a survey. 探索炎症性肠病中身体活动的障碍：来自一项调查的见解。

IF 1.8 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2026-09-24 DOI: 10.1080/00365521.2026.2736875

Christophe Souaid, Anne Buisson, Marine Jeay, Florence Skinazi, Stéphane Nahon

{"title":"Exploring obstacles to physical activity in inflammatory bowel disease: insights from a survey.","authors":"Christophe Souaid, Anne Buisson, Marine Jeay, Florence Skinazi, Stéphane Nahon","doi":"10.1080/00365521.2026.2736875","DOIUrl":"https://doi.org/10.1080/00365521.2026.2736875","url":null,"abstract":"Background: Regular physical activity is recommended in Inflammatory Bowel Disease (IBD) and improves fatigue, psychological well-being and quality of life. However, many patients remain insufficiently active, and barriers to exercise are incompletely understood. This study aimed to explore patient-reported obstacles to physical activity and to assess awareness of and interest in Adapted Physical Activity (APA) programs for IBD.Methods: A national cross-sectional survey was conducted from June to October 2021 among adults with IBD (≥18 years), recruited through a French patient association's social networks and 12 gastroenterology centers. The self-completed online questionnaire collected demographic and disease-related data, assessed physical activity using the International Physical Activity Questionnaire (IPAQ), and evaluated a pre-specified list of exercise barriers and awareness of APA. Disease activity was self-reported.Results: Among 538 patients (71% female; mean age 37.7 ± 11.2 years; 55% Crohn's disease, 43% ulcerative colitis; 35% self-reported active disease), 79% engaged in moderate-to-vigorous and 21% in low activity by IPAQ. During flares, the main barriers were fatigue (76%), abdominal pain (64%), diarrhea (64%) and limited restroom access (38%). Persistent barriers included need for tailored advice (28%), lack of motivation (25%), joint pain (25%), social isolation (21%), financial constraints (20%) and fear of judgement or symptom worsening. Only 16% were aware of APA, whereas 60% expressed interest, particularly in supervised or group-based formats.Conclusions: IBD patients face symptom-related and psychosocial barriers to physical activity. Despite low awareness, strong interest in APA supports integrating structured, personalized exercise programs into routine IBD care.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-3"},"PeriodicalIF":1.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149040526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of additional hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: an updated systematic review and meta-analysis. 附加腹腔热化疗对胃癌伴腹膜转移的疗效：一项最新的系统评价和荟萃分析。

IF 1.8 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2026-09-21 DOI: 10.1080/00365521.2026.2736872

Jingni Cao, Ting Jiang, Qi Wu, Kangshuo Hu, Shiyan Zhang, Qingping Wu, Yujie Shu

{"title":"Efficacy of additional hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: an updated systematic review and meta-analysis.","authors":"Jingni Cao, Ting Jiang, Qi Wu, Kangshuo Hu, Shiyan Zhang, Qingping Wu, Yujie Shu","doi":"10.1080/00365521.2026.2736872","DOIUrl":"https://doi.org/10.1080/00365521.2026.2736872","url":null,"abstract":"Background: The survival benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer with peritoneal metastasis (PM) remains controversial. This study evaluates the efficacy of HIPEC in these patients.Methods: We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library (from inception to August 2026) to identify randomized controlled trials (RCTs) and cohort studies evaluating the efficacy of HIPEC in gastric cancer with PM. The primary endpoint was overall survival (OS). Pooled hazard ratios (HRs) and 95% confidence intervals (95%CIs) were calculated using a random-effects model. The study protocol was registered in PROSPERO (CRD420261332944).Results: Nine studies, including four RCTs and five cohort studies, were included in the meta-analysis. Patients receiving additional HIPEC had significantly better OS than those in the control group (HR = 0.71, 95%CI: 0.56-0.91; p = 0.008). In subgroup analyses, patients receiving additional HIPEC showed better OS than those in the control group in studies combined with cytoreductive surgery (CRS) (HR = 0.64, 95%CI: 0.50-0.80; p < 0.001), Western studies (HR = 0.67, 95%CI: 0.53-0.85; p < 0.001), and cohort studies (HR = 0.63, 95%CI: 0.55-0.72; p < 0.001). In contrast, studies using additional HIPEC showed no significant OS benefit in RCTs, Eastern studies, studies without CRS, or the subgroups defined by HIPEC drug regimen.Conclusions: In the overall analysis, additional HIPEC was associated with longer OS in patients with gastric cancer and PM, particularly in studies in which HIPEC was combined with CRS. However, the apparent survival benefit was mainly observed in observational cohort studies and was not confirmed in the pooled analysis of RCTs.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-11"},"PeriodicalIF":1.8,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic and severity value of the neutrophil-to-lymphocyte ratio in patients with acute diverticulitis: a systematic review with meta-analysis. 急性憩室炎患者中性粒细胞与淋巴细胞比值的预后和严重程度价值：一项荟萃分析的系统综述。

IF 1.8 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2026-09-21 DOI: 10.1080/00365521.2026.2731965

Patricio Castro-Suárez, Alvaro Montes-Baldarrago, Jeffrey Mora-Arévalo, Miguel Cabanillas-Lazo

{"title":"Prognostic and severity value of the neutrophil-to-lymphocyte ratio in patients with acute diverticulitis: a systematic review with meta-analysis.","authors":"Patricio Castro-Suárez, Alvaro Montes-Baldarrago, Jeffrey Mora-Arévalo, Miguel Cabanillas-Lazo","doi":"10.1080/00365521.2026.2731965","DOIUrl":"https://doi.org/10.1080/00365521.2026.2731965","url":null,"abstract":"Objective: This study evaluates the neutrophil-to-lymphocyte ratio (NLR) as a potential tool for assessing acute diverticulitis (AD) severity and prognosis.Methods: A systematic search was conducted in PubMed, Embase, Scopus, Web of Science and Google Scholar. A meta-analysis compared mean NLR values between complicated and non-complicated AD patients and those who underwent surgery versus non-surgical management.Results: Seventeen cohort studies were included. NLR >7.2 predicted mortality (sensitivity: 80%, specificity: 60%). The optimal NLR cutoff for predicting complicated AD was 4.862, with sensitivity of 74.17% (95% CI: 56.25%; 86.51%) and specificity of 68.41% (95% CI: 52.84%; 80.71%). The mean NLR was higher in the surgical group (MD: 2.85; 95% CI: -0.24; 5.95; I2: 86%). High NLR was associated with failure of non-surgical treatment (OR: 1.65; 95% CI: 0.47; 3.90).Conclusion: NLR may be a useful biomarker for AD severity and mortality risk. However, its relevance for predicting surgery need, treatment failure or recurrence is limited. Larger, prospective are needed to confirm its clinical utility.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0